- Epirubicin
Epirubicin is an
anthracycline drug used forchemotherapy . It is marketed byPfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin "Ebewe" elsewhere.Similarly to other anthracyclines, epirubicin acts by intercalating
DNA strands.Intercalation results in complex formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage bytopoisomerase II , resulting in mechanisms that lead to cell death. Binding to cell membranes and plasma proteins may be involved in the compound's cytotoxic effects. Epirubicin also generatesfree radical s that cause cell and DNA damage.Epirubicin is favoured over
doxorubicin , the most popular anthracycline, in somechemotherapy regimen s as it appears to cause fewer side-effects. Epirubicin has a different spatial orientation of the hydroxyl group at the 4' carbon of the sugar, which may account for its faster elimination and reduced toxicity. Epirubicin is primarily used against breast and ovarian cancer, gastric cancer, lung cancer, and lymphomas.Development history
The first trial of epirubicin in humans was published in 1980. [cite journal| title=Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia|author=Bonfante, V|journal=Recent results in cancer research|pages=192–9|year=1980|volume=74 |id= PM6934564]
Upjohn applied forFDA approval in node-positive breast cancer in 1984, but was turned down because of lack of data. [cite web| url=http://www.targethealth.com/ontarget/1999/061399.htm |title=On Target] It appears to have been licensed for use in Europe from around this time however. [According to the proprietary database iddb.com] In 1999Pharmacia (who had by then merged with Upjohn) received FDA approval for the use of epirubicin as a component of adjuvant therapy in node-positive patients.Patent protection for epirubicin expired in August 2007.
References
External links
* http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Epirubicin.htm
* http://www.pfizeroncology.com/products/ellence.aspx
Wikimedia Foundation. 2010.